You are here

  • Home
  • Archive
  • Volume 13, Issue 4
  • Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: azathioprine, infliximab, certolizumab, and adalimumab are effective for maintaining remission in Crohn’s disease

https://doi.org/10.1136/ebm.13.4.115

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A K Akobeng

    Dr A K Akobeng, Booth Hall Children’s Hospital, Manchester, UK; tony.akobeng@cmmc.nhs.uk

    QUESTION

    Which interventions are effective for maintaining remission in Crohn’s disease?

    REVIEW SCOPE

    Included studies evaluated interventions for maintaining remission in Crohn’s disease. Outcome was maintenance of remission (or relapse).

    REVIEW METHODS

    Medline (1966 to May 2007), Cochrane Library (Issue 2, 2007), and Cochrane Inflammatory Bowel Disease Group were searched for randomised controlled trials (RCTs) or systematic reviews or meta-analyses of RCTs. 8 interventions (azathioprine, 5-aminosalicylates, corticosteroids, budesonide, antimycobacterial agents, probiotics, omega-3 fatty acids, and enteral nutrition) were evaluated in systematic reviews, and 6 interventions (methotrexate, infliximab, adalimumab, natalizumab, certolizumab, and ciclosporin) were evaluated in RCTs. …

    View Full Text

    Footnotes

    • Source of funding: no external funding.